News

January 14, 2021January 14, 2021

Canada Approves Onureg, Oral Chemotherapy for AML Patients in Remission

News

Health Canada has approved Onureg, an oral formulation of the chemotherapy azacitidine, as the first maintenance therapy for adults with acute myeloid leukemia (AML) who have achieved complete remission after intensive induction chemotherapy. ... Read more

January 7, 2021January 7, 2021

Ascentage Pharma’s APG-2575 Earns Orphan Drug Designation

News

APG-2575, an investigational Bcl-2 inhibitor being developed by Ascentage Pharma, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia ... Read more

January 4, 2021January 4, 2021

CPI-613 on FDA Fast Track to Treat AML

News

CPI-613 (devimistat) has been granted a fast track designation by the U.S. Food and Drug Administration to treat acute myeloid leukemia (AML), announced its developer, Rafael Pharmaceuticals. The designation is ... Read more

December 21, 2020December 21, 2020

NexImmune, City of Hope Partner to Research NEXI-001, New Therapies

News

NexImmune and City of Hope have teamed up on a research initiative aimed at advancing treatment candidate NEXI-001 for acute myeloid leukemia (AML) and identifying new targets for future therapies. ... Read more

December 17, 2020December 17, 2020

Venclexta Combos Approved in Canada to Treat Newly Diagnosed AML

News

Health Canada has approved Venclexta (venetoclax) in combination with Vidaza (azacitidine) or low-dose cytarabine to treat newly diagnosed adults, ages 75 and older, with acute myeloid leukemia (AML), who have other ... Read more

December 14, 2020December 17, 2020

Potential Cancer Vaccine DCP-001 May Control AML Residual Disease

News

DCP-001, the lead cancer vaccine candidate by DCprime, safely elicited a tumor-specific immune response in patients with acute myeloid leukemia (AML), who still showed signs of residual disease despite having ... Read more

December 10, 2020December 10, 2020

OSU Names Leukemia Research Center in Honor of Scientist Clara Bloomfield

News

Clara D. Bloomfield dedicated her career to finding new treatments for patients with acute myeloid leukemia (AML) and related disorders. To continue the work of its longtime faculty member, Ohio State ... Read more

December 7, 2020December 7, 2020

First-in-Human Trial Testing NKX101 Natural Killer Cell Therapy Treats First Patient

News

The first patient has received treatment in a first-in-human Phase 1 trial of NKX101, Nkarta‘s investigational cell therapy for the treatment of relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic ... Read more

December 2, 2020December 3, 2020

FDA Puts Eprenetapopt on Fast Track for Treating TP53 Mutant AML

News

Eprenetapopt (APR-246), an investigational therapy being developed by Aprea Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration for treating acute myeloid leukemia (AML) with mutations in the TP53 gene. ... Read more

November 30, 2020November 30, 2020

NORD Push for Rare Disease Advisory Councils Focus of Dec. 16 Public Meeting

News, syndicated

To empower and equip members of the rare disease community to engage state leaders in matters of importance to patients and their families, the National Organization for Rare Disorders (NORD) ... Read more